(224 days)
The RX Daytona Plus Chemistry analyzer is a bench top fully automated random access clinical chemistry analyzer intended for use in clinical laboratories. It is intended to be used for a variety of assay methods. The RX Daytona Plus includes an optional Ion Selective Electrode (ISE) module for the measurement of sodium, potassium and chloride in serum and urine. The RX Daytona Plus is not for Point-Of-Care testing.
Sodium measurements are used in the diagnosis and treatment of diseases involving electrolyte imbalance.
Potassium measurements monitor electrolyte balance in the diagnosis and treatment of disease conditions characterized by low or high blood potassium levels.
Chloride measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders.
The RX Daytona Plus AST reagent is for the quantitative in vitro diagnostic determination of the activity of the enzyme Aspartate aminotransferase (AST) in human serum. Aspartate amino transferase measurements are used in the diagnosis and treatment of certain types of liver and heart diseases.
The RX Daytona Plus is a bench-top fully automated random access clinical analyser intended for use in clinical laboratories.
The RX Daytona Plus contains an ISE .module for the measurement of Potassium, Chloride and Sodium. The RX Daytona Plus has the capacity to perform up to 270 photometric tests or 450 tests per hour with ISE's and offers primary tube sampling, on-board sample dilution and a cooled reagent compartment.
- Cuvette wash system .
- STAT facility .
- Direct interface with host computer .
- . Automatic re-run and pre-dilution functions
The RX Daytona Plus uses dedicated software for easy access to all system facilities and functions. operating functions and provides a comprehensive data management system.
Reagents:
AST reagent is supplied in a kit containing:
- . 4 x 20.0 mL Buffer/ enzyme
- . 4 x 7.0 mL α-οχοςlutarate/Coenzyme.
The primary reagent contains L-Aspartic acid, MDH, Tris Buffer and preservative, The secondary reagent contains a-oxoglutarate, NADH and preservatives.
ISE Electrodes, Sodium, Potassium and Chloride are comprised of ISE Calibrator H and L, ISE diluent, ISE reference solution and ISE etching solution.
Here's a summary of the acceptance criteria and study information for the RX Daytona Plus Instrument, based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria for this device are implied by the results of the precision, linearity, detection limit, analytical specificity, and method comparison studies. The device aims to demonstrate substantial equivalence to its predicate devices for each analyte (AST, Sodium, Potassium, Chloride) in the relevant sample types (serum, urine). The performance metrics reported directly represent if these implied criteria were met.
| Performance Characteristic | Analyte | Sample Type | Acceptance Criteria (Implied) | Reported Device Performance |
|---|---|---|---|---|
| Precision (Total CV) | AST | Serum | Low variability | 1.4% - 12.2% |
| Sodium | Serum | Low variability | 1.1% - 3.1% | |
| Sodium | Urine | Low variability | 4.3% - 5.6% | |
| Potassium | Serum | Low variability | 1.3% - 3.9% | |
| Potassium | Urine | Low variability | 2.7% - 4.4% | |
| Chloride | Serum | Low variability | 1.6% - 3.6% | |
| Chloride | Urine | Low variability | 3.0% - 6.3% | |
| Linearity (R²) | AST | Serum | Close to 1.0 | 1.000 (Range: 5 – 1116 U/L) |
| Sodium | Serum | Close to 1.0 | 0.999 (Range: 90 – 226 mmol/L) | |
| Sodium | Urine | Close to 1.0 | 0.998 (Range: 45 – 318 mmol/L) | |
| Potassium | Serum | Close to 1.0 | 0.999 (Range: 0.5 – 11 mmol/L) | |
| Potassium | Urine | Close to 1.0 | 1.000 (Range: 1.5 – 168 mmol/L) | |
| Chloride | Serum | Close to 1.0 | 0.998 (Range: 72 – 210 mmol/L) | |
| Chloride | Urine | Close to 1.0 | 0.999 (Range: 61 – 319 mmol/L) | |
| Detection Limit | AST | Serum | Defined LoD/LoQ | LoD: 1.372 U/L, LoQ: 5 U/L |
| Analytical Specificity | All | Serum/Urine | No significant interference | Varies by interferent (see tables 12-15). Note: Hemoglobin interferes with AST and Potassium; Bromide, Thiocyanate, and Salicylic acid interfere with Chloride and Potassium. |
| Method Comparison (r) | AST | Serum | High correlation to predicate | 0.999 |
| Sodium | Serum | High correlation to predicate | 0.990 | |
| Sodium | Urine | High correlation to predicate | 0.996 | |
| Potassium | Serum | High correlation to predicate | 0.997 | |
| Potassium | Urine | High correlation to predicate | 0.999 | |
| Chloride | Serum | High correlation to predicate | 0.990 | |
| Chloride | Urine | High correlation to predicate | 0.997 | |
| Expected Values | All | Serum | Fall within established ranges | All values reported in the range for Healthy Individuals (for Na, K, Cl) |
2. Sample Sizes Used for the Test Set and Data Provenance
-
Precision/Reproducibility:
- AST, Sodium, Potassium, Chloride (Serum): Two levels of control material, calibration material, unaltered human serum samples, and altered human serum samples. Tested twice per day for 20 non-consecutive days, with two replicates per sample. This totals approximately 80 test points per sample type for control/calibrator, and 40 test points per patient pool (20 days * 2 replicates).
- Sodium, Potassium, Chloride (Urine): Two levels of urine controls and two urine patient pools. Tested twice per day for 20 non-consecutive days, with two replicates per sample. Totals approximately 80 test points per control, and 40 test points per patient pool.
- Data Provenance: Not explicitly stated, but the submission is from Randox Laboratories Limited in the United Kingdom, suggesting the studies were likely conducted there. The samples were human serum and urine. Retrospective or prospective nature is not specified, but the "non-consecutive days" suggests prospective testing over a period.
-
Linearity/Assay Reportable Range:
- AST, Sodium, Potassium, Chloride (Serum & Urine): Studies performed at 11 levels.
- Data Provenance: Implied to be derived from the UK.
-
Detection Limit (AST):
- 360 determinations, with 1 blank and 2 low-level samples.
- Data Provenance: Implied to be derived from the UK.
-
Analytical Specificity (Interference):
- Interferents (Hemoglobin, Bilirubin, Triglycerides, Intralipid, various drugs) were "spiked" into relevant control/sample solutions. The number of samples/replicates isn't specified beyond this.
- Data Provenance: Implied to be derived from the UK.
-
Method Comparison with Predicate Device:
- AST (Serum): 92 serum patient samples.
- Sodium (Serum): 50 serum patient samples.
- Sodium (Urine): 42 urine patient samples.
- Potassium (Serum): 56 serum patient samples.
- Potassium (Urine): 43 urine patient samples.
- Chloride (Serum): 61 serum patient samples.
- Chloride (Urine): 44 urine patient samples.
- All samples were tested in singlicate across 5 working days.
- Data Provenance: Not explicitly stated, but given the submitter's location (UK), the data is most likely from the UK. The studies used "patient samples," which suggests real-world specimens, likely collected prospectively for the purpose of the study or retrospectively from a patient cohort.
-
Expected Values/Reference-range Verification:
- Sodium, Potassium, Chloride (Serum): Human serum from 30 normal donors, tested in singlicate.
- Data Provenance: Implied to be derived from the UK.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications
Not applicable. This device is a clinical chemistry analyzer. The "ground truth" for the test set values (e.g., concentrations of AST, sodium) is established by reference methods or validated laboratory procedures, not by human expert interpretation like in imaging studies. The predicate device's performance also serves as a benchmark.
4. Adjudication Method for the Test Set
Not applicable. Adjudication methods (like 2+1, 3+1) are typically used for establishing ground truth in subjective diagnostic tasks, such as radiology image interpretation. In this context, the "ground truth" values for chemical analytes are obtained through highly standardized and quantitative laboratory methods (e.g., reference methods, predicate device results).
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done
No. An MRMC study is relevant for evaluating the impact of AI on human readers' performance in diagnostic tasks (e.g., radiology). This device is a fully automated chemistry analyzer, not an AI-assisted diagnostic tool for human readers.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was Done
Yes, essentially all the performance data (precision, linearity, detection limits, analytical specificity, method comparison) reflects the standalone performance of the RX Daytona Plus Chemistry Analyzer as an automated instrument. There is no human-in-the-loop aspect for the analysis itself; human intervention is only involved in loading samples and interpreting the final results generated by the machine.
7. The Type of Ground Truth Used
The ground truth for the performance studies was established using a combination of:
- Reference materials/control materials: For precision and linearity studies.
- Validated methods/Predicate device results: For method comparison studies, where the results from the RX Daytona Plus were compared against a legally marketed predicate device (Randox RX Imola Chemistry Analyzer with ISE, Randox AST assay).
- Gravimetric preparation from purified salts: For ISE (Sodium, Potassium, Chloride) calibrators traceability.
- Standardized reference procedures (JSCC TS01): For AST traceability.
- Clinical literature: For establishing expected values/reference ranges.
8. The Sample Size for the Training Set
Not applicable. This is a traditional automated chemistry analyzer, not a machine learning or AI-driven device that requires a training set in the typical sense. The "parameters" and "algorithms" (e.g., Nernst equation for ISE, kinetic reaction for AST) are based on established chemical and physical principles, not learned from a large dataset.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as there is no "training set" for this type of device. The operating principles are based on fundamental scientific laws and established chemical diagnostic assays.
{0}------------------------------------------------
KI 31554
510(K) Summary RX Daytona Plus Instrument
510(K) SUMMARY
JAN - 9 2014
1. SAFETY AND EFFECTIVENESS AS REQUIRED BY 21 CFR 807.92 STATEMENT
This summary of the 510(k) safety and effectiveness information is being submitted in accordance with the requirement 21 CFR 807.92.
2. SUBMITTER NAME AND ADDRESS
Name: Randox Laboratories Limited
Address: 55 Diamond Road, Crumlin, County Antrim, BT29 4QY, United Kingdom.
Telephone: +44 (0) 28 9442 2413 Fax: +44 (0) 28 9445 2912
Contact: Dr Pauline Armstrong E-mail: Pauline.Armstrong@randox.com
3. 510k NUMBER, DEVICE PROPRIETARY NAME, COMMON NAME. PURPOSE FOR SUBMISSION, REGULATORY CLASSIFCATION, PANEL. PRODUCT CODE AND 21 CFR NUMBER
| Product Code | Regulation Name | Classification | Regulation Section | Panel |
|---|---|---|---|---|
| CIT | Aspartate aminotransferase (AST/SGOT)Test system | II | 21 CFR 862.1100 | Chemistry (75) |
| JGS | Sodium Test System | II | 21 CFR 862.1665 | Chemistry (75) |
| CEM | Potassium Test System | II | 21 CFR 862.1600 | Chemistry (75) |
| CGZ | Chloride Test System | II | 21 CFR 862.1170 | Chemistry (75) |
| JJE | Discrete photometricchemistry analyzer forclinical use | I | 21 CFR 862.2160 | Chemistry (75) |
{1}------------------------------------------------
Proprietary Names: RX Daytona Plus Chemistry Analyzer; RX Daytona Plus AST Reagent
4. PREDICATE DEVICE PROPRIETARY NAME AND 510 (k) NUMBER
Randox RX Imola Chemistry Analyzer with ISE Sodium, Potassium and Chloride electrodes K052914.
Randox AST assay K923505.
5. DEVICE DESCRIPTION
RX Daytona plus system
The RX Daytona Plus is a bench-top fully automated random access clinical analyser intended for use in clinical laboratories.
The RX Daytona Plus contains an ISE .module for the measurement of Potassium, Chloride and Sodium. The RX Daytona Plus has the capacity to perform up to 270 photometric tests or 450 tests per hour with ISE's and offers primary tube sampling, on-board sample dilution and a cooled reagent compartment.
- Cuvette wash system .
- STAT facility .
- Direct interface with host computer .
- . Automatic re-run and pre-dilution functions
The RX Daytona Plus uses dedicated software for easy access to all system facilities and functions. operating functions and provides a comprehensive data management system.
Reagents
AST reagent is supplied in a kit containing:
- . 4 x 20.0 mL Buffer/ enzyme
- . 4 x 7.0 mL α-οχοςlutarate/Coenzyme.
The primary reagent contains L-Aspartic acid, MDH, Tris Buffer and preservative, The secondary reagent contains a-oxoglutarate, NADH and preservatives.
ISE Electrodes, Sodium, Potassium and Chloride are comprised of ISE Calibrator H and L, ISE diluent, ISE reference solution and ISE etching solution.
{2}------------------------------------------------
6. TEST PRINCIPLE
RX Daytona plus system Operation
After a sample cup or patient tube is placed into the sample carousel, the analyser pipettes the sample into the cuvette, pipettes the reagent and mixes the sample and reagent together in the reaction cuvette. After the sample and reagent react the analyser measures the absorbance of the sample and based on the absorbance reactions for the analyte being measured, it calculates the concentration of the analyte in the sample. The test system can measure analytes from multiple matrices including serum and urine. The time to first result is approximately 13 minutes.
Test Principle for ISE Unit
Measuring procedure, sodium, potassium and chloride:
ISE unit measures ionic concentration in sample with ion-selective electrode (ISE). It converts the activity of a specific ion dissolved in a solution into an electrical potential, according to the Nernst equation (below) Serum samples are measured by direct ISE method. Urine samples are prediluted with dedicated diluents and measured.
E=E0 + RT/nF x log a
- E: Sample potential
- E0 : Reference potential
- R : Gas constant
- T : Absolute temperature (K)
- n : lonic valance
- F : Faraday constant (C)
- a : lon activity
Calculation of calibration slope
Slope is calculated according to the subtraction of H solution potential and L solution potential:
S = (EH-EL) / log (CH / CL)
- S : Slope (mV/decade) EH : H solution potential EL : L solution potential CH : H solution concentration CL : L solution concentration
3
{3}------------------------------------------------
Measurement
Sample concentration is obtained by measuring sample potential and L solution potential and calculated according to the slope which is obtained through the calibration.
C = CL x 10 ^ { ( E - EL ) / S }
- C : Sample concentration
- CL: L solution concentration
- E : Sample potential
- EL . L solution potential
- S : Slope (mV/decade
Process of analysis
-
- Dispense sample into the sample port of the ISE module, with the sample probe (SPT).
-
- Sample is delivered to electrodes.
-
- Sample potential is measured.
-
- Liquid in the flow path is wasted.
-
- The flow path is cleaned with L solution.
-
- L solution is delivered to electrodes.
-
- L solution potential is measured.
-
- Sample concentration is obtained by calculation according to sample potential and L solution potential.
-
- Output the measurement result.
Test Principle for Chemistry Reactions
Randox AST Assay:
«-oxoglutarate reacts with L-aspartate in the presence of AST to form L-qlutamate plus oxaloacetate. The indicator reaction utilizes the oxaloacetate for a kinetic determination of NADH consumption.
AST -oxoglutarate + → L-aspartate L-glutamate + oxaloacetate
MDH oxaloacetate + NADH + H* L-malate + NAD*
The ISE unit measures the concentration of Sodium (Na), Potassium (K) and Chloride (CI) contained in serum and urine by using ion specific electrodes.
{4}------------------------------------------------
(510(K) Summary RX Daytona Plus Instrument NDIOF
7. INTENDED USE
The RX Daytona Plus Chemistry analyzer is a bench top fully automated ran d o m a c c s clinical chemistry analyzer intended for use in clinical laboratories. It is intended to be used for a variety of assay methods. The RX Davtona Plus includes an optional lon Selective Electrode (ISE) module for the measurement of sodium, potassium and chloride in serum and urineThe RX Daytona Plus is not for Point-Of-Care testing.
Sodium measurements are used in the diagnosis and treatment of diseases involving electrolyte imbalance.
Potassium measurements monitor electrolyte balance in the diagnosis and treatment of disease conditions characterized by low or high blood potassium levels.
Chloride measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders.
The RX Daytona Plus AST reagent is for the quantitative in vitro diagnostic determination of the activity of the enzyme Aspartate aminotransferase (AST) in human serum. Aspartate amino transferase measurements are used in the diagnosis and treatment of certain types of liver and heart diseases.
8. COMPARISON WITH PREDICATE
The following table describes the similarities and differences between the two systems.
{5}------------------------------------------------
Table 1 Technical Specification of the RX Daytona Plus and the RX Imola
| Parameter | RX Imola Automated Analyzer(K052914) Predicate | RX Daytona Plus AutomatedAnalyser |
|---|---|---|
| Manufacturer | Furuno Electric Co. Ltd Japan onbehalf of Randox Laboratories | Same |
| DeviceClassification | Chemistry Analyser(Photometric, Discrete) for | Same |
| Analyzerdescription: | High throughput, fully automated,random access bench topchemistry analyzer | Same |
| Dimensions | 970mm (W) x 690mm (D) x 580mm(H) | 870mm (W) ×670mm (D) ×625mm(H) |
| Intended use: | An In vitro fully quantitativeanalyzer. The analyzer can beused to run tests including AST inserum samples. Various otherassays are adaptable to theanalyzer. The RX Imola analyzerand ISE unit must only be used bysuitably qualified personnel, underappropriate laboratory conditions. | Same |
| Assay Tests | Endpoint, Kinetic,Bichromatic, turbidmetric,sample blanking, reagentblanking and ISE. | Monochromatic, bi-chromatic,endpoint, kinetic, sample and reagentblanking and ISE (via optionalintegrated ISE) |
| CalibrationPrinciple | Factor, Linear, 2 point, point topoint, spline, log-logit,exponential and ISE | Factor, Linear, Point to point, Log-logit, Exponential, Spline, Spline 2and ISE |
| Cuvettes | 90 reusable pyrex cuvettes(volume, 150ul min, 450ul max) | 72 resin cuvettes (semi-disposable)(volume, 100ul min, 350ul max) |
| Cycle Time | 9 seconds | 13 seconds |
| DetectionPrinciple | 12 wavelengths generated viadiffraction grating: 340, 380,415,450,510,546,570,600,660,700,750 | Same |
| Detector Method | Direct absorbance in cuvette(bichromatic and monochromatic) | Same |
| Data Management | Storage of up to 10, 000patient reports, searchfacility | Storage of up to 30, 000 reports,search facility |
| Parameter | RX Imola AutomatedAnalyzer | RX Daytona Plus AutomatedAnalyser |
| Light Source | Halogen Tungsten Lamp | Same |
| LIMSConnectivity | Bi-directional; ASTMStandard | Same |
| Maintenance | Daily maintenance-lessthan5minutes. No rear accessrequired. Simple twice yearly | Same |
| Analysismethod: | Photometric | Same |
| Sample type: | Serum, urine | Same |
| SampleAddition | Sampling interruption for additionof samples | Same |
| Sample Volume | Normal Sample: 2-35µl | Normal Sample: 1.5-35µl |
| SampleCapacity | Removable tray with 72 positionsfor samples in outer ring, 20positions for calibrators andcontrols in the inner ring. | Removable tray with 40 positions forsamples in outer ring, 10 positions forcalibrators and controls in the innerring. |
| SampleDilution | Pre-diluted and automatic re-assay with diluted, reduced andincreased sample volume | Same |
| SampleIdentification | Barcode sample identification | Same |
| Sample Pipette | Dedicated sample micropipettewith liquid level sensor, crashprotection and clot detection | Same |
| Sample DeadVolume | 100ul in standard or primarytubes, | Same |
| Sample TubeSize | Multiple primary tubesizes(diameter12 to 16mm, height 55 to | Same |
| ReagentCapacity | Removable tray with 60cooled positions | Removable tray with 50 cooledpositions |
| ReagentCooling | 8- | Same |
| ReagentIdentification | Automatic barcodereagent | Same |
| ReagentInventory | Calculation of remainingreagent volume and testsavailable. Alerts for shortage, | Same |
.
{6}------------------------------------------------
Image /page/6/Picture/0 description: The image shows the text "RANDOX 510(K) Summary RX Daytona Plus Instrument". The text appears to be a title or heading, possibly related to a medical or scientific instrument. The text is black and the background is white. The text is left-aligned.
Table 1 Technical Specification of the RX Daytona Plus and the RX Imola Cont..
.
{7}------------------------------------------------
| Table 1 Technical Specification of the RX Daytona Plus and the RX Imola Cont |
|---|
| ------------------------------------------------------------------------------ |
| Parameter | RX Imola Automated Analyzer(K052914) Predicate | RX Daytona Plus AutomatedAnalyser |
|---|---|---|
| Reagentpipette | Two Dedicated reagentmicropipette with liquid levelsensor and crash detection. Rinsedinside and outside with purified | One Dedicated reagent micropipettewith liquid level sensor and crashdetection. Rinsed inside and outsidewith purified water |
| ReagentpipetteSamplingVolume | R1:20-350ul (1ul increments)R2: 20-2501ul (1ulincrements) | R1:20-250ul (1ul increments)R2: 20-180ul (1ul increments) |
| Minimum reactionvolume | 150ul | 100ul |
| MaximumHumidity | 45-85% without condensation | 45-85% without condensation |
| IncubationTemperature | 37°C +/-0.3 | 37°C +/-0.1 |
| Stirring System | Stick type rotating stirrer withvariable speed to promoteeven mixing in all types of | Same |
| Stirring Speed | Dual 5 speed rotating stirrers | 5 speed levels available |
| STAT sampling | STAT samples can be addedimmediately via emergencyloading port | Same |
| Throughput | Capable of running 400 tests perhour, 560 tests per hour with | Capable of running 270 tests per hour,450 tests per hour with ISE |
| Test Channels | 60 photometric channels, 3 directISE (Total 63 channels) | 50 photometric channels, 3 direct ISE(Total 53 channels) |
| WaterConsumption | Maximum 18L per hour | Maximum 5L per hour |
| Parameter | RX Imola AutomatedAnalyzer(K052914 | RX Daytona Plus AutomatedAnalyzer ISE Module |
| Sample | Serum, orUrine(Urine: automatic 10 fold dilution | Serum or Urine(Urine: automatic 7 times dilution) |
| Sample size | 10ul Serum, (70ulx3) + 50ul Urine | 50ul |
| Reproducibility | ||
| Na KCl | Serum (WithinRun) :CV <1.5%(100-160mmol/L) CV <2% (3.0-6.0mmol/L) CV <1.5% (80-120mmol/L) | Serum (Within Run)CV <1.0% (120-160mmol/L)CV <1.5% (2-6mmol/L)CV <1.2% (80-120mmol/L) |
| Na KCl | Urine (Within Run) CV<5% (20-500mmol/L) | Urine (Within Run)CV <3.8% (80-200mmol/L)CV <3.8% (20-150mmol/L) |
| Na KCl | CV <5% (1-500mm ol/L) CV <5% (20-500mmol/L) | CV <3.8% (70-140mmol/L) |
| Serum (Between days)CV <2.0%(100- | Serum (Between Days)CV <2.0% (140mmol/L)CV <2.0% (5mmol/L)CV <2.0% (100mmol/L) | |
| Analysis Time | Serum:30 secondsUrine 100 seconds | Serum 36 secondsUrine 54 seconds |
| Throughput | Serum 240 tests perhour,80 samples perhour | Serum 300 tests per hourUrine 200 tests per hour |
| MaxTemperature | 37°C | Same |
| CalibrationFrequency | 24 hours (main calibration) After ISEcleaning, | Same |
| Reagentsrequired | Calibrator A (Cal Abag) Calibrator BCleaningsolution | L SolutionH solutionISE Cleaning solution Etchingsolution (Na cleaning) UrineDiluent |
| Parameter | RX Imola Automated Analyzer(K052914) | RX Daytona Plus AutomatedAnalyzer ISE Module |
| Intendeduse | CAL A and CAL B are used in the calibrationof sodium, potassium and chloride on the RXImola ISE module - | ISE Calibrators are used for the calibration ofsodium (Na+), potassium (K+) and chloride(CI-) on the RX Daytona Plus analyzerequipped with ISE module. |
| Analyte | Sodium , Potassium , Chloride | Same:Sodium , Potassium , Chloride |
| Composition | Aqueous solution containing sodium,potassium and chloride at two different levelsof concentration.CAL ANa+ = 140mmol/lK+ = 4mmol/lCl- = 125 mmol/lCAL BNa+ = 70mmol/lK+ = 8mmol/lCl- = 41 mmol/l | Aqueous solution containing sodium,potassium and chloride at two different levelsof concentration.L Solution Na+ =120mmol/l K+ =4mmol/lCl- = 100 mmol/lH Solution Na+= 200mmol/l K+ =7mmol/lCl- = 150 mmol/l |
| Form | Liquid ready to use | Same |
| Storage(opened) | Once opened CAL A is stable for 2 monthsonboard the analyzer.CAL B is stable for 1 month when stored at+15 to +25°C | Once opened L Solution and H Solution arestable for 1 month at +15 to +25°C |
| Storage(Unopened) | Stable to the expiration date at +15 to +25°C | Stable to the expiration date at +15 to +25°C |
The RX Daytona Plus analyzer has the same intended use as the predicate device. Any differences in the technical characteristics of the RX Daytona Plus and the predicate device do not affect the safety or effectiveness. Therefore, the RX Daytona Plus analyzer demonstrates substantial equivalence to the predicate device
{8}------------------------------------------------
Table 2 Technical Specifications of the RX Daytona Plus ISE Module and the RX Imola Analyzer ISE Module
The RX Daytona Plus analyzer ISE unit has the same intended use as the predicate device. Any differences in the technical characteristics of the RX Daytona Plus ISE unit and the predicate device do not affect the safety or effectiveness. Therefore, the RX Daytona Plus analyzer ISE unit demonstrates substantial equivalence to the predicate device.
9
{9}------------------------------------------------
Image /page/9/Picture/0 description: The image shows the text "RANDOX 510(K) Summary RX Daytona Plus Instrument". The text is in a sans-serif font and is black. The word "RANDOX" is in a larger font size than the rest of the text. The text is centered on the image.
Table 3 Technical Specifications of the RX Daytona Plus ISE Calibrators and the RX Imola Analyzer ISE Calibrators
The RX Daytona Plus analyzer ISE Calibrators have the same intended use as the predicate device. Any differences in the technical characteristics of the RX Daytona Plus ISE Calibrators and the predicate device do not affect the safety or effectiveness. Therefore, the RX Daytona Plus analyzer ISE Calibrators demonstrates substantial equivalence to the predicate device.
{10}------------------------------------------------
Table 4 Technical Specifications of the AST predicate device with AST on the RX Daytona plus Analyzer ISE Module.
| CHARACTERISTICS | RANDOX AST REAGENTON THE RX IMOLAANALYZER K052914/A001 | RX Daytona Plus ASTREAGENT |
|---|---|---|
| Intended Use | The AST test system is a deviceintended for the quantitative invitro determination of aspartateaminotransferase (AST) activity inserum and plasma.Measurements of AST are usedin the diagnosis and treatment ofcertain types of liver and heartdisease | Same |
| Assay Protocol | UV Method | Same |
| Format | Liquid which are ready to use | Same |
| Storage(unopened) | Reagents are stable up to theexpiry date when storedunopened at +2 to +8°C | Same |
| Sample Type | Plasma and serum | Serumonly |
| Control Frequency | Randox assayed humanmultisera Level 2 & 3Two levels of control should beassayed at least once a day | Same |
| Calibration Frequency | Every 28 days, with a change ofreagent lot or as indicated byquality control procedures. | Same |
| Materials required but notprovided | Randox assayed humanmultisera Level 2 & 3. RandoxCalibration Sera level 3. RXSeries Saline. | Same |
{11}------------------------------------------------
9. PERFORMANCE CHARACTERISTICS
Analytical performance:
a. Precision/Reproducibility:
Precision was evaluated consistent with C.L.S.I documents EP5 Precision studies were performed on one RX Daytona plus system using two levels of control material, calibration material, unaltered human serum samples and altered human serum samples for AST. Sodium, Potassium and Chloride. Urine precision studies were performed for Sodium, Potassium and Chloride using two levels of urine controls and two urine patient pools. Testing was conducted twice per day for 20 non consecutive days. Two replicates per run was performed for each sample. The results are summarized in the tables below:
Table 2 AST Precision Summary
| System: RX Daytona Plus | Within Run | Among Run | Among Day | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Method | Product | MEAN(U/L) | SD | CV | SD | CV | SD | CV | SD | CV |
| AST | Control538UE | 161.74 | 2.23 | 1.4 | 1.08 | 0.7 | 1.03 | 0.6 | 2.69 | 1.7 |
| AST | Control738UN | 37.83 | 1.14 | 3.0 | 0.62 | 1.6 | 0.00 | 0.0 | 1.29 | 3.4 |
| AST | Calibrator(532UE) | 142.95 | 1.82 | 1.3 | 1.25 | 0.9 | 0.04 | 0.0 | 2.20 | 1.5 |
| AST | HIGHSerumPool | 391.33 | 2.26 | 0.6 | 5.16 | 1.3 | 7.61 | 1.9 | 9.47 | 2.4 |
| AST | NORMALSerumPool | 18.83 | 0.43 | 2.3 | 0.70 | 3.7 | 0.71 | 3.8 | 1.08 | 5.8 |
| AST | 850 u/LSerumPool | 850.27 | 4.57 | 0.5 | 6.75 | 0.8 | 8.29 | 1.0 | 11.62 | 1.4 |
| AST | LOWSerumPool | 6.68 | 0.53 | 8.0 | 0.49 | 7.3 | 0.37 | 5.6 | 0.81 | 12.2 |
{12}------------------------------------------------
| System: RX Daytona Plus | Within Run | Among Run | Among Day | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Method | Product | MEAN(mmol/l)) | SD | CV | SD | CV | SD | CV | SD | CV |
| Sodium | Control538UE | 154.03 | 2.15 | 1.4 | 3.04 | 2.0 | 0.00 | 0.0 | 3.72 | 2.4 |
| Sodium | Control738UN | 138.75 | 1.60 | 1.2 | 4.01 | 2.9 | 0.00 | 0.0 | 4.32 | 3.1 |
| Sodium | PatientPool 1 | 108.83 | 1.75 | 1.6 | 0.00 | 0.0 | 0.59 | 0.5 | 1.85 | 1.7 |
| Sodium | PatientPool 2 | 134.62 | 1.40 | 1.0 | 0.00 | 0.0 | 0.43 | 0.3 | 1.46 | 1.1 |
| Sodium | PatientPool 3 | 174.60 | 2.08 | 1.2 | 1.11 | 0.6 | 1.68 | 1.0 | 2.90 | 1.7 |
Table 3 Sodium Serum Precision Summary
Table 4 Sodium Urine Precision Summary
| System: RX Daytona Plus | Within Run | Among Run | Among Day | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Method | Product | MEAN(mmol/l)) | SD | CV | SD | CV | SD | CV | SD | CV |
| Sodium | Control575UC | 61.84 | 2.59 | 4.2 | 2.12 | 3.4 | 0.80 | 1.3 | 3.44 | 5.6 |
| Sodium | Control580UC | 192.25 | 6.21 | 3.2 | 3.77 | 2.0 | 5.87 | 3.1 | 9.34 | 4.9 |
| Sodium | PatientPool 1 | 135.65 | 4.05 | 3.0 | 2.65 | 2.0 | 5.75 | 4.2 | 7.51 | 5.5 |
| Sodium | PatientPool 2 | 281.59 | 5.37 | 1.9 | 6.58 | 2.3 | 8.50 | 3.0 | 12.02 | 4.3 |
:
Table 5 Potassium Serum Precision Summary
.
| System: RX Daytona Plus | Within Run | Among Run | Among Day | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Method | Product | MEAN(mmol/l) | SD | CV | SD | CV | SD | CV | SD | CV |
| Potassium | Control538UE | 6.01 | 0.06 | 1.1 | 0.04 | 0.7 | 0.02 | 0.3 | 0.08 | 1.3 |
| Potassium | Control738UN | 4.01 | 0.06 | 1.4 | 0.03 | 0.7 | 0.02 | 0.6 | 0.07 | 1.7 |
| Potassium | PatientPool 1 | 3.28 | 0.13 | 3.9 | 0.00 | 0.0 | 0.02 | 0.8 | 0.13 | 3.9 |
| Potassium | PatientPool 2 | 4.62 | 0.09 | 1.9 | 0.00 | 0.0 | 0.03 | 0.6 | 0.09 | 2.0 |
| Potassium | PatientPool 3 | 6.74 | 0.08 | 1.2 | 0.05 | 0.7 | 0.06 | 0.9 | 0.11 | 1.7 |
·
.
{13}------------------------------------------------
| System: RX Daytona Plus | Within Run | Among Run | Among Day | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Method | Product | MEAN (mmol/l)) | SD | CV | SD | CV | SD | CV | SD | CV |
| Potassium | Control 575UC | 32.69 | 0.55 | 1.7 | 0.34 | 1.0 | 0.72 | 2.2 | 0.97 | 3.0 |
| Potassium | Control 580UC | 103.23 | 2.08 | 2.0 | 2.45 | 2.4 | 3.17 | 3.1 | 4.52 | 4.4 |
| Potassium | Patient Pool 1 | 31.86 | 0.57 | 1.8 | 0.46 | 1.4 | 0.47 | 1.5 | 0.87 | 2.7 |
| Potassium | Patient Pool 2 | 84.26 | 2.04 | 2.4 | 0.77 | 0.9 | 2.04 | 2.4 | 2.98 | 3.5 |
Table 6 Potassium Urine Precision Summary
Table 7 Chioride Serum Precision Summary
·
| System: RX Daytona Plus | Within Run | Among Run | Among Day | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Method | Product | MEAN(mmol/l) | SD | CV | SD | CV | SD | CV | SD | CV |
| Chloride | Control538UE | 114.86 | 1.29 | 1.1 | 1.00 | 0.9 | 1.07 | 0.9 | 1.95 | 1.7 |
| Chloride | Control738UN | 100.35 | 1.40 | 1.4 | 0.00 | 0.0 | 0.73 | 0.7 | 1.58 | 1.6 |
| Chloride | PatientPool 1 | 88.84 | 1.87 | 2.1 | 0.47 | 0.5 | 0.18 | 0.2 | 1.94 | 2.2 |
| Chloride | PatientPool 2 | 106.11 | 3.52 | 3.3 | 1.48 | 1.4 | 0.00 | 0.0 | 3.81 | 3.6 |
| Chloride | PatientPool 3 | 134.13 | 1.75 | 1.3 | 1.75 | 1.3 | 0.26 | 0.2 | 2.49 | 1.9 |
Table 8 Chloride Urine Precision Summary
.
| System: RX Daytona Plus | MEAN (mmol/l)) | Within Run | Among Run | Among Day | Total | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Method | Product | SD | CV | SD | CV | SD | CV | SD | CV | |
| Chloride | Control 575UC | 86.44 | 3.15 | 3.6 | 2.70 | 3.1 | 2.12 | 2.5 | 4.66 | 5.4 |
| Chloride | Control 580UC | 240.25 | 5.23 | 2.2 | 4.38 | 1.8 | 13.41 | 5.6 | 15.04 | 6.3 |
| Chloride | Patient Pool 1 | 171.06 | 4.98 | 2.9 | 5.34 | 3.1 | 0.00 | 0.0 | 7.30 | 4.3 |
| Chloride | Patient Pool 2 | 260.24 | 3.74 | 1.4 | 5.61 | 2.2 | 3.82 | 1.5 | 7.75 | 3.0 |
・
{14}------------------------------------------------
b. Linearity/assay reportable range:
Linearity studies have been carried out in accordance with C.L.S.I. standard EP6-A. Linearity studies were performed at 11 levels to determine the analytical range of an assay - that is the range where the reported result is a linear function to the analyte concentration (or where deviation from linearity is less than 5%).
The results are summarized in the following tables:
Table 9 Serum Linearity Summary
| Analyte | Linear regression | Reportable Range |
|---|---|---|
| AST | $y=1.00x+0.65; R^2=1.000$ | 5 – 1116U/L |
| Sodium | $y=1.05x-5.45; R^2=0.999$ | 90 – 226 mmol/l |
| Potassium | $y=1.02x-0.13; R^2=0.999$ | 0.5 – 11 mmol/l |
| Chloride | $y=0.99x+1.14; R^2=0.998$ | 72 – 210 mmol/l |
Table 10 Urine Linearity Summary
| Analyte | Linear regression | Reportable Range |
|---|---|---|
| Sodium | $y=0.95x+7.26; R^2=0.998$ | 45 – 318 mmol/l |
| Potassium | $y=1.03x-1.20; R^2=1.000$ | 1.5 – 168 mmol/l |
| Chloride | $y=0.96x+3.41;R^2=0.999$ | 61 – 319 mmol/l |
| Analyte | Serum ReportableRange | Urine ReportableRange | |||
|---|---|---|---|---|---|
| Sodium | 90 - 226mmol/l | 45 — 318 mmol/l | |||
| Potassium | 0.5 - 11 mmol/l | 1.5 – 168 mmol/l | |||
| Chloride | 72 — 210 mmol/l | 61 - 319 mmol/l |
{15}------------------------------------------------
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
See K955489 Calibrator and K942458 Control for AST and K052914 for ിട്ടല
Table 11 Traceability Table Randox AST Reagent and ISE's Sodium, Potassium and Chloride
| Analyte | Reference Material | |
|---|---|---|
| AST | Standardized against primary calibrators traceable to ASTreference material JSCC TS01 | |
| ISE: Sodium,Potassiumand Chloride | Standardized against primary calibrators preparedgravimetrically from purified salts. |
d. Detection limit:
Sensitivity studies have been carried out in accordance with C.L.S.I. guideline EP17-A 'Protocols for Determination of Limits of Detection and Limits of Quantification; Approved Guideline'. A Limit of Blank (L.o.B.), a Limit of Detection (L.o.D.) and a Limit of Quantification were performed on the RX Daytona Plus.
AST
The Limit of Detection (LoD) for AST on the RX Daytona Plus is 1.372 U/L based on 360 determinations, with 1 blank and 2 low level samples.
The Limit of Blank (LoB) is 0.50 U/L.
The Limit of Quantitation (LoQ) is 5 U/L as determined by the lowest concentration at which precision and accuracy are still met. Acceptable criteria ≤20% accuracy and ≤20% imprecision.
{16}------------------------------------------------
e. Analytical Specificity:
The effects of potential interferents were determined by calculating the mean value of the spiked interferent with the corresponding control solution.
Hemoglobin, Bilirubin, Triglycerides and Intralipid tested up to the following levels and were found not to interfere with the AST assay.
Table 12 AST Interference Summary
| Interferent | AST @ 35 U/L |
|---|---|
| Hemoglobin | Interferes |
| Bilirubin (F) | 60 mg/dl |
| Bilirubin (C) | 60 mg/dl |
| Intralipid ® | 500 mg/dl |
| Triglycerides | 500 mg/dl |
The analytes below were tested in serum up to the following levels and were found not to interfere with Sodium, Potassium and Chloride:
Table 13 ISE Sodium, Potassium and Chloride Serum Interference Summary
| Concentration | |||
|---|---|---|---|
| Interferent | Sodium @125 mmol/l | Potassium @2.95 mmol/l | Chloride @90 mmol/l |
| Hemoglobin | 500 mg/dl | * Interferes | 750 mg/dl |
| Bilirubin (F) | 60 mg/dl | 60 mg/dl | 30 mg/dl |
| Bilirubin (C) | 60 mg/dl | 60 mg/dl | 60 mg/dl |
| Intralipid ® | 2000 mg/dl | 1500 mg/dl | 2000 mg/dl |
| Triglycerides | 2000 mg/dl | 2000 mg/dl | 2000 mg/dl |
- Use non-hemolyzed samples as significant hemolysis will elevate AST and potassium levels.
{17}------------------------------------------------
A panel of drugs causes no significant interferences up to the indicated concentrations except Thyiocyanate and Salicylic acid which causes artificially elevated Chloride concentrations and Bromide which causes artificially elevated Chloride and Potassium concentrations.
Table 14 ISE Sodium, Potassium and Chloride Serum Exogenous Interference Summary
| InterferingSubstance | Concentration ofinterferent spiked into140 mmol/l Sodium | Concentration ofinterferent spiked into3.4 mmol/l Potassium | Concentration ofinterferent spiked into108 mmol/l Chloride |
|---|---|---|---|
| Bromide | 37.5mmol/L | Interference observed<9.38mmol/l | Interference observed<9.38mmol/l |
| AscorbicAcid | 342mmol/L | 342mmol/L | 342mmol/L |
| Thiocyanate | 6.88mmol/L | 6.88mmol/L | Interference observed<1.72mmol/l |
| Lithium | 3.2mmol/L | 3.2mmol/L | 3.2mmol/L |
| SalicylicAcid | 4.34mmol/L | 4.34mmol/L | Interference observed<1.085mmol/l |
Urine Summary
The analytes below were tested in urine up to the following levels and were found not to interfere with Sodium, Potassium, and Chloride.
Table 15 ISE Sodium, Potassium and Chloride Urine Interference Summary
| Concentration | ||||
|---|---|---|---|---|
| Interferent | Sodium @ 80 mmol/l | Potassium @ 21 mmol/l | Chloride @ 261 mmol/l | |
| Hemoglobin | 500 mg/dl | 500 mg/dl | 750 mg/dl | |
| Bilirubin (F) | 60 mg/dl | 60 mg/dl | 30 mg/dl | |
| Bilirubin (C) | 30 mg/dl | 60 mg/dl | 45 mg/dl | |
| Intralipid ® | 2000 mg/dl | 2000 mg/dl | 1500 mg/dl | |
| Triglycerides | 2000 mg/dl | 2000 mg/dl | 2000 mg/dl |
{18}------------------------------------------------
f. Method comparison with predicate device:
Correlation studies were carried out in accordance with C.L.S.I. guideline EP9-A2 'Method Comparison and Bias Estimation Using Patient Samples: Approved Guideline - Second Edition'.
AST:
92 serum patient samples spanning the range 5 to 817U/L were tested on the RX Daytona plus analyzer across 5 working days with each sample tested in singlicate. The test method was compared to the predicate device and the following linear regression equation was obtained:
Y = 1.03x + 2.33 Correlation coefficient of r = 0.999
Sodium: Serum
50 serum patient samples spanning the range 105 to 194mmol/l were tested on the RX Daytona plus analyzer across 5 working days with each sample tested in singlicate. The test method was compared to the predicate device and the following linear regression equation was obtained:
Y = 1.04x - 9.57 Correlation coefficient of r = 0.990
Sodium: Urine
42 urine patient samples spanning the range 54.9 to 288.5mmo/l were tested on the RX Daytona plus analyzer across 5 working days with each sample tested in singlicate. The test method was compared to the predicate device and the following linear regression equation was obtained:
Y = 1.01x - 7.99 Correlation coefficient of r = 0.996
{19}------------------------------------------------
Potassium: Serum
56 serum patient samples spanning the range 0.75 to 9.58mmol/l were tested on the RX Daytona plus analyzer across 5 working days with each sample tested in singlicate. The test method was compared to the predicate device and the following linear regression equation was obtained:
Y = 1.02x = 0.13 Correlation coefficient of r = 0.997
Potassium Urine
43 urine patient samples spanning the range 10.63 to 145.06mmoll were tested on the RX Daytona plus analyzer across 5 working days with each sample tested in singlicate. The test method was compared to the predicate device and the following linear regression equation was obtained:
Y = 1.04x - 1.48 Correlation coefficient of r = 0.999
Chloride: Serum
61 serum patient samples spanning the range 81.3 to 189.3mmol/l were tested on the RX Daytona plus analyzer across 5 working days with each sample tested in singlicate. The test method was compared to the predicate device and the following linear regression equation was obtained:
Y = 1.03x - 1.16 Correlation coefficient of r = 0.990
Chloride: Urine
44 urine patient samples spanning the range 74.05 to 287.2mmoll were tested on the RX Daytona plus analyzer across 5 working days with each sample tested in singlicate. The test method was compared to the predicate device and the following linear regression equation was obtained:
Y = 0.97x + 5.08 Correlation coefficient of r = 0.997
{20}------------------------------------------------
510(K) Summary RX Daytona Plus Instrument
g. Expected values/Reference-range:
Referenced from literature
Reference intervals for the ISEs were verified using NCCLS C28-A2 guidelines. In a study, human serum from 30 normal donors were tested in singlicate on the RX daytona plus. The results obtained were ordered from lowest to highest before being examined for outliers using the Dixon test.
Upon confirmation there were no outliers, the values were compared to the quoted ranges for Sodium, Potassium and Chloride. Results of the study indicate that all values reported in the range for Healthy Individuals.
| Analyte | Serum | Urine |
|---|---|---|
| AST1 | Men-Up to 35 U/L;Women up to 31 U/L | n/a |
| Sodium (Na*)² | 136-145 mmol/l | 40-220 mmol/24h |
| Potassium (K*)² | 3.5-5.1 mmol/l | 25-125 mmol/24h |
| Chloride (Cl~)2 | 98-107 mmol/l | 110-250 mmol/24h |
1 Schumann G, Klauke R. New IFCC reference procedures for the determination of catalytic activity concentrations of five enzymes in serum; preliminary upper reference limits obtained in hospitalized subjects. Clin Chem Acta 2003; 327 (1-2) 69-79.
2 Tietz NW, Pruden EL, Siggaard-Andersen O. Electrolytes. In: Burtis CA, Ashwood ER, eds. Tietz Textbook of Clinical Chemistry. 2nd ed. Philadelphia: WB Saunders 1994:1354-1374.
It is recommended that each laboratory establish its own reference range to reflect the age, sex, diet and geographical location of the population.
10. CONCLUSION
Testing results indicate that the proposed devices (RX Daytona Plus analyzer and Daytona Plus AST reagent ) are safe and effective for the stated intended use and are substantially equivalent to the predicate devices.
{21}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/21/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with its wings spread, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle. The logo is black and white and appears to be a scanned image.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 January 9, 2014
RANDOX LABORATORIES, LTD. DR. PAULINE ARMSTRONG, QA/RA MANAGER 55 DIAMOND RD. CRUMLIN, COUNTY ANTRIM BT29 4QY UK
Re: K131554
Trade/Device Name: RX Daytona Plus Chemistry Analyzer, RX Daytona Plus Aspartate Aminotransferase (AST) Reagent
Regulation Number: 21 CFR 862.1100 Regulation Name: Aspartate amino transferase (AST/SGOT) test system Regulatory Class: II Product Code: CIT, JGS, CEM, CGZ, JJE Dated: November 29, 2013 Received: November 30, 2013
Dear Ms. Armstrong:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in intersted commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Or to and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{22}------------------------------------------------
If you desire specific advice for your device on our labeling regulations (2) CFR Parts 801 and 809), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Sotsonet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.itm. Also, plaase note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its roll free number (800) 638-2041 or (30.1) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Courtney H. Lias -S
Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
{23}------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known)
K131554
Device Name Daytona Plus Chemistry analyzer
Daytona Plus Aspartate Aminotransferase (AST) reagent
Indications for Use (Describe)
The RX Daytona Plus Chemistry analyzer is a bench top fully automated random access clinical chemistry analyzer intended for use in clinical laboratories. It is intended to be used for a variety of assay methods. The RX Daytona Plus includes an optional Ion Selective Electrode (ISE) module for the measurement of sodium, potassium and chloride in serum and urine. The RX Daytona Plus is not for Point-Of-Care testing.
Sodium measurements are used in the diagnosis and treatment of diseases involving electrolyte imbalance.
Potassium measurements monitor electrolyte balance in the diagnosis and treatment of disease conditions characterized by low or high blood potassium levels.
Chloride measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders.
The RX Daytona Plus AST reagent is for the quantitative in vitro diagnostic determination of the activity of the enzyme Aspartate aminotransferase (AST) in human serum. Aspartate amino transferase measurements are used in the diagnosis and treatment of certain types of liver and heart diseases.
Type of Use (Select one or both, as applicable)
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
中国人民共和国际网址 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | oncurrence of Center for Devices and Radiological Health (CDRH) (Signature)
Image /page/23/Picture/17 description: The image shows the text "YungFWDchan-S". The text is written in a bold, sans-serif font. The letters "FWD" are stylized with a geometric pattern. The text is black and white.
FORM FDA 3881 (9/13)
Page 1 of
Misting Services (301) 443-6740
§ 862.2160 Discrete photometric chemistry analyzer for clinical use.
(a)
Identification. A discrete photometric chemistry analyzer for clinical use is a device intended to duplicate manual analytical procedures by performing automatically various steps such as pipetting, preparing filtrates, heating, and measuring color intensity. This device is intended for use in conjunction with certain materials to measure a variety of analytes. Different models of the device incorporate various instrumentation such as micro analysis apparatus, double beam, single, or dual channel photometers, and bichromatic 2-wavelength photometers. Some models of the device may include reagent-containing components that may also serve as reaction units.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.